FDA's New and Supplemental Approvals in December

The FDA wrapped up the year with the approval of at least nine new therapies in December. Among these approvals was a subcutaneous formulation of Opdivo, which could play a crucial role in extending the product's lifecycle. This development comes at a time when the IV versions of major PD-1 inhibitors are facing impending patent cliffs, highlighting the importance of innovation and adaptation in the pharmaceutical industry.